Literature DB >> 20080624

ATM is down-regulated by N-Myc-regulated microRNA-421.

Hailiang Hu1, Liutao Du, Gindy Nagabayashi, Robert C Seeger, Richard A Gatti.   

Abstract

Ataxia-telangiectasia mutated (ATM) is a high molecular weight protein serine/threonine kinase that plays a central role in the maintenance of genomic integrity by activating cell cycle checkpoints and promoting repair of DNA double-strand breaks. Little is known about the regulatory mechanisms for ATM expression itself. MicroRNAs are naturally existing regulators that modulate gene expression in a sequence-specific manner. Here, we show that a human microRNA, miR-421, suppresses ATM expression by targeting the 3'-untranslated region (3'UTR) of ATM transcripts. Ectopic expression of miR-421 resulted in S-phase cell cycle checkpoint changes and an increased sensitivity to ionizing radiation, creating a cellular phenotype similar to that of cells derived from ataxia-telangiectasia (A-T) patients. Blocking the interaction between miR-421 and ATM 3'UTR with an antisense morpholino oligonucleotide rescued the defective phenotype caused by miR-421 overexpression, indicating that ATM mediates the effect of miR-421 on cell cycle checkpoint and radiosensitivity. Overexpression of the N-Myc transcription factor, an oncogene frequently amplified in neuroblastoma, induced miR-421 expression, which, in turn, down-regulated ATM expression, establishing a linear signaling pathway that may contribute to N-Myc-induced tumorigenesis in neuroblastoma. Taken together, our findings implicate a previously undescribed regulatory mechanism for ATM expression and ATM-dependent DNA damage response and provide several potential targets for treating neuroblastoma and perhaps A-T.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080624      PMCID: PMC2824372          DOI: 10.1073/pnas.0907763107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  The DNA damage response: putting checkpoints in perspective.

Authors:  B B Zhou; S J Elledge
Journal:  Nature       Date:  2000-11-23       Impact factor: 49.962

2.  ATM is a target for positive regulation by E2F-1.

Authors:  Eli Berkovich; Doron Ginsberg
Journal:  Oncogene       Date:  2003-01-16       Impact factor: 9.867

Review 3.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

4.  Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway.

Authors:  Risa Kitagawa; Christopher J Bakkenist; Peter J McKinnon; Michael B Kastan
Journal:  Genes Dev       Date:  2004-06-02       Impact factor: 11.361

5.  Radioresistant DNA synthesis: an intrinsic feature of ataxia telangiectasia.

Authors:  R B Painter
Journal:  Mutat Res       Date:  1981-11       Impact factor: 2.433

6.  Effect of ionizing radiation on DNA synthesis in ataxia telangiectasia cells.

Authors:  J Houldsworth; M F Lavin
Journal:  Nucleic Acids Res       Date:  1980-08-25       Impact factor: 16.971

Review 7.  ATM and related protein kinases: safeguarding genome integrity.

Authors:  Yosef Shiloh
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

Review 8.  Neuroblastoma: biological insights into a clinical enigma.

Authors:  Garrett M Brodeur
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

9.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation.

Authors:  Christopher J Bakkenist; Michael B Kastan
Journal:  Nature       Date:  2003-01-30       Impact factor: 49.962

10.  Nonaminoglycoside compounds induce readthrough of nonsense mutations.

Authors:  Liutao Du; Robert Damoiseaux; Shareef Nahas; Kun Gao; Hailiang Hu; Julianne M Pollard; Jimena Goldstine; Michael E Jung; Susanne M Henning; Carmen Bertoni; Richard A Gatti
Journal:  J Exp Med       Date:  2009-09-21       Impact factor: 14.307

View more
  115 in total

Review 1.  Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation.

Authors:  Liqin Du; Alexander Pertsemlidis
Journal:  J Mol Cell Biol       Date:  2011-01-28       Impact factor: 6.216

Review 2.  Crosstalk between the DNA damage response pathway and microRNAs.

Authors:  Cecil Han; Guohui Wan; Robert R Langley; Xinna Zhang; Xiongbin Lu
Journal:  Cell Mol Life Sci       Date:  2012-03-20       Impact factor: 9.261

3.  Inducible deletion of epidermal Dicer and Drosha reveals multiple functions for miRNAs in postnatal skin.

Authors:  Monica Teta; Yeon Sook Choi; Tishina Okegbe; Gabrielle Wong; Oliver H Tam; Mark M W Chong; John T Seykora; Andras Nagy; Dan R Littman; Thomas Andl; Sarah E Millar
Journal:  Development       Date:  2012-04       Impact factor: 6.868

4.  Posttranscriptional regulation of miRNAs in the DNA damage response.

Authors:  Xinna Zhang; Xiongbin Lu
Journal:  RNA Biol       Date:  2011-11-01       Impact factor: 4.652

Review 5.  MicroRNAs: new players in the DNA damage response.

Authors:  Hailiang Hu; Richard A Gatti
Journal:  J Mol Cell Biol       Date:  2010-12-23       Impact factor: 6.216

Review 6.  Genomic integrity and the ageing brain.

Authors:  Hei-man Chow; Karl Herrup
Journal:  Nat Rev Neurosci       Date:  2015-10-14       Impact factor: 34.870

Review 7.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

Review 8.  Charity begins at home: non-coding RNA functions in DNA repair.

Authors:  Dipanjan Chowdhury; Young Eun Choi; Marie Eve Brault
Journal:  Nat Rev Mol Cell Biol       Date:  2013-02-06       Impact factor: 94.444

9.  Non-coding RNAs in DNA damage response.

Authors:  Yunhua Liu; Xiongbin Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 10.  MicroRNAs in the ionizing radiation response and in radiotherapy.

Authors:  Chanatip Metheetrairut; Frank J Slack
Journal:  Curr Opin Genet Dev       Date:  2013-02-28       Impact factor: 5.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.